HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Janssen Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Janssen Intelligence Report

Generated from 36 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Jul 24, 2026

Confidence

Moderate Confidence · 69%

Evidence

198 items

Sources

37

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Janssen maintains an active intelligence profile across Diabetes, SGLT2 Inhibitor, Oncology, Monoclonal Antibody, Immunology. 36 signals are linked with 2 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 69% across 3 tracked sources. Highest-priority development: Medical Products for Rare Diseases and Conditions. Regulatory precedent. Why this matters: provides agency context on orphan designation that may shape timing or evidence expectations for Roche.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. investigateJun 16, 2026

    Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis

    Neurology · Alzheimer's Disease · opportunity score 160

    View detail
  2. investigateJun 20, 2026

    FDA Approves OTC Naloxone Nasal Spray Rextovy for Opioid Overdose

    Neurology · Opioid Overdose · opportunity score 155

    View detail
  3. regulatory

    Medical Products for Rare Diseases and Conditions

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    Data Standards Program Strategic Plan and Board

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    Research: Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD risk

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    Notice: Register of authorised online sellers of medicines in Northern Ireland

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Research: Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD risk

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — CANAGLIFLOZIN (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — SPORANOX (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA AP — ERLEADA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA AP — ERLEADA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 5407 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: High. 2 investigate-priority signals warrant near-term portfolio review.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Medical Products for Rare Diseases and Conditions

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Data Standards Program Strategic Plan and Board

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Research: Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD risk

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • Notice: Register of authorised online sellers of medicines in Northern Ireland

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • Research: Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD risk

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • FDA AP — CANAGLIFLOZIN (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SPORANOX (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ERLEADA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ERLEADA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — DARZALEX (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — STELARA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — TECVAYLI (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Investigational New Drug (IND) Application

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SPORANOX (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis

    Neurology · Alzheimer's Disease

  • FDA Approves OTC Naloxone Nasal Spray Rextovy for Opioid Overdose

    Neurology · Opioid Overdose

  • Janssen's Amivantamab Study in Advanced NSCLC Evaluates Safety and Efficacy

    Oncology · NSCLC

  • Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Detection

    Neurology · Alzheimer's Disease

  • FDA Approves Supplemental Application for REXTOVY by Amphastar Pharmaceuticals

    Neurology · Opioid Overdose

  • FDA Approves Supplement for Levetiracetam by Chartwell RX

    Neurology · Antiepileptic

  • FDA Accepts Supplement for INVOKANA (Canagliflozin) by Janssen

    Diabetes · SGLT2 Inhibitor

  • FDA Accepts Supplement for TREMFYA (Guselkumab) by Janssen Biotech

    Immunology · IL-23

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.